This platinum complex serves as a key intermediate in the synthesis of platinum-based antitumor agents, such as oxaliplatin, used in chemotherapy for solid tumors including colorectal, ovarian, and lung cancers. The final drugs derived from it bind to DNA, inducing cross-links that disrupt replication and transcription, leading to apoptosis in cancer cells. Its specific (1R-trans) stereochemistry enables the production of agents with improved selectivity and reduced nephrotoxicity compared to cisplatin. Ongoing research explores its role in developing targeted therapies leveraging its controlled reactivity.